1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

After a general alignment of the company’s structures, Roche was left with four core business sectors – pharmaceuticals, vitamins and fine chemicals, diagnostics, and flavours and fragrances.